Eczema Free Forever™

Buoyed by new eczema data, AnaptysBio hits the fundraising button – FierceBiotech


FierceBiotech
Buoyed by new eczema data, AnaptysBio hits the fundraising button
FierceBiotech
After a single dose of ANB020, 75% of the 12 enrolled patients achieved an Eczema Area Severity Index score improvement of 50% (EASI-50) or more at day 15, 83% of patients at day 29 and 75% of patients achieved EASI-50 after 57 days or around two …
This Biotech Hit Record High; Could Undercut Regeneron In EczemaInvestor’s Business Daily
AnaptysBio Inc. (ANAB) Announces Positive Topline Proof-of-Concept Data from Phase 2A Clinical Trial of ANB020StreetInsider.com

all 70 news articles »

eczema – Google News

Eczema Free Forever™